DrugPatentWatch Database Preview
Talazoparib tosylate - Generic Drug Details
What are the generic drug sources for talazoparib tosylate and what is the scope of patent protection?
Talazoparib tosylate
is the generic ingredient in one branded drug marketed by Pfizer Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Talazoparib tosylate has seventy-three patent family members in twenty-seven countries.
Two suppliers are listed for this compound.
Summary for talazoparib tosylate
| International Patents: | 73 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 7 |
| Clinical Trials: | 4 |
| Patent Applications: | 7 |
| DailyMed Link: | talazoparib tosylate at DailyMed |
Recent Clinical Trials for talazoparib tosylate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Melinda Telli | Phase 2 |
| National Cancer Institute (NCI) | Phase 2 |
| BioMarin Pharmaceutical | Phase 0 |
Pharmacology for talazoparib tosylate
| Drug Class | Poly(ADP-Ribose) Polymerase Inhibitor |
| Mechanism of Action | Poly(ADP-Ribose) Polymerase Inhibitors |
Synonyms for talazoparib tosylate
| (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido(4,3,2-de)phthalazin-3-one MONO(4-methylbenzenesulfonate) |
| (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt |
| 02WK9U5NZC |
| 1373431-65-2 |
| 3H-Pyrido(4,3,2-de)phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-, (8S,9R)-, 4-methylbenzenesulfonate (1:1) |
| BMN 673TS |
| BMN-673TS |
| CHEMBL3137318 |
| CS-0028593 |
| D10733 |
| EX-A1357 |
| HY-108413 |
| QUQKKHBYEFLEHK-QNBGGDODSA-N |
| SCHEMBL2717160 |
| Talazoparib pound BMN-673 pound(c)tosylate |
| Talazoparib tosylate (USAN) |
| Talazoparib tosylate [USAN] |
| Talzenna (TN) |
| UNII-02WK9U5NZC |
US Patents and Regulatory Information for talazoparib tosylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-002 | Oct 16, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Pfizer Inc | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-001 | Oct 16, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Pfizer Inc | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-002 | Oct 16, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Pfizer Inc | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-001 | Oct 16, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Pfizer Inc | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-002 | Oct 16, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Pfizer Inc | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-001 | Oct 16, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for talazoparib tosylate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 362563 | Start Trial |
| South Africa | 201100897 | Start Trial |
| Denmark | 2326650 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2012054698 | Start Trial |
| Japan | 2011530513 | Start Trial |
| Japan | 5984389 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.